secwatch.observer — SEC 8-K summary
======================================

Issuer:     ASSEMBLY BIOSCIENCES, INC. (ASMB)
CIK:        0001426800
Form:       8-K/A
Filed at:   2026-08-14T20:05:17+00:00
Accession:  0001193125-26-352193
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Assembly Bio Q2 net loss narrows to $3.9M; cash $320.4M, pipeline advances
--------------------------------------------------------------------------

- Q2 net loss $3.9M ($0.20/share) vs $10.2M ($1.33) year ago; Gilead revenue $13.4M vs $9.6M.
- Cash, equivalents, marketable securities $320.4M at June 30, 2026; $115M gross financing completed; runway into 2029.
- ABI-6250 expanded into cholestatic liver diseases (PBC, PSC); Phase 2 expected Q1 2027.
- GS-1179 selected for Phase 2 in recurrent genital herpes by year-end 2026; opt-in decision on 40% U.S. cost-profit share pending Gilead cost estimates.
- $75M Gilead extension payment due Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1426800/000119312526352193/0001193125-26-352193-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1426800/000119312526352193/asmb-20260813.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-352193

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer